PRNewsWire · October 24, 2026

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

Get the app for more

Explore stock news, insights and company research.